Search results for Lintuzumab

Lintuzumab Biosimilar – Anti-CD33 mAb – Research Grade, ProteoGenix, PX-TA1046

Description of Lintuzumab Biosimilar - Anti-CD33 mAb - Research Grade Introduction to Lintuzumab Biosimilar – Anti-CD33 mAb Lintuzumab Biosimilar, also known as Anti-CD33 mAb, is a monoclonal antibody that targets the CD33 protein, which is found on the surface of certain cancer cells. It is a highly specific and potent therapeutic agent that has shown promising results in the treatment of various types of cancer. In this article, we will explore the structure, activity, and potential applications of Lintuzumab Biosimilar as a research grade antibody. Structure of Lintuzumab Biosimilar – Anti-CD33 mAb Lintuzumab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, meaning it is produced in the laboratory using genetic engineering techniques. It is composed of two heavy chains and two light chains, each containing specific regions that are responsible for its binding and therapeutic activity. The variable regions of the antibody are designed to specifically recognize and bind to the CD33 protein, while the constant regions provide stability and effector functions. Mechanism of Action of Lintuzumab Biosimilar – Anti-CD33 mAb The primary mechanism of action of Lintuzumab Biosimilar is through its binding to the CD33 protein on cancer cells. This binding triggers a series of events that ultimately leads to the destruction of the cancer cell. Lintuzumab Biosimilar can also activate the body’s immune system to target and eliminate cancer cells through a process called antibody-dependent cellular cytotoxicity (ADCC). Title: Applications of Lintuzumab Biosimilar – Anti-CD33 mAb Lintuzumab Biosimilar has shown promising results in the treatment of various types of cancer, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). It has also been investigated for its potential in treating other types of cancer such as acute lymphoblastic leukemia (ALL) and solid tumors. As a research grade antibody, Lintuzumab Biosimilar can also be used in laboratory studies to further understand the role of CD33 in cancer and to develop new therapeutic strategies. Title: Clinical Trials and Results of Lintuzumab Biosimilar – Anti-CD33 mAb Several clinical trials have been conducted to evaluate the safety and efficacy of Lintuzumab Biosimilar in cancer patients. In a phase II study, Lintuzumab Biosimilar was shown to be well-tolerated and had a favorable impact on the survival of AML patients. Another phase II study in MDS patients also demonstrated promising results, with a significant reduction in the risk of disease progression. Currently, Lintuzumab Biosimilar is being evaluated in combination with other therapies in clinical trials for AML and other types of cancer. Title: Advantages and Limitations of Lintuzumab Biosimilar – Anti-CD33 mAb One of the main advantages of Lintuzumab Biosimilar is its high specificity and potency, which minimizes off-target effects and maximizes its therapeutic activity. It also has a favorable safety profile, making it a suitable candidate for combination therapies. However, its effectiveness may be limited in certain patients who do not express high levels of CD33 on their cancer cells. Future Directions and Potential of Lintuzumab Biosimilar – Anti-CD33 mAb As research on Lintuzumab Biosimilar continues, there is potential for its use in other types of cancer and as a targeted therapy in combination with other treatments. Additionally, further understanding of the role of CD33 in cancer could lead to the development of new and improved versions of Lintuzumab Biosimilar with enhanced therapeutic activity. In conclusion, Lintuzumab Biosimilar – Anti-CD33 mAb is a highly specific and potent monoclonal antibody with promising results in the treatment of various types of cancer. Its structure, mechanism of action, and potential applications make it a valuable tool for both research and clinical use. With ongoing studies and advancements in the field, Lintuzumab Biosimilar has the potential to

Lintuzumab, Abbexa, abx831012

Lintuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD33, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).

Lintuzumab ELISA Kit, ProteoGenix, KPTX206

Description of Lintuzumab ELISA Kit Introduction Lintuzumab is a monoclonal antibody that has been developed as a therapeutic agent for the treatment of acute myeloid leukemia (AML). It specifically targets the CD33 antigen, which is overexpressed on the surface of leukemic cells in AML patients. The Lintuzumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Lintuzumab in various biological samples. In this article, we will discuss the structure, activity, and application of the Lintuzumab ELISA Kit in the field of AML research. Structure of Lintuzumab Lintuzumab is a chimeric monoclonal antibody, meaning it is composed of both human and mouse components. It is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions of Lintuzumab are responsible for its binding specificity to the CD33 antigen, while the constant regions are responsible for its effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Activity of Lintuzumab The main activity of Lintuzumab is its ability to bind to the CD33 antigen on the surface of leukemic cells. This binding leads to the activation of immune effector cells, such as natural killer cells and macrophages, which then target and kill the leukemic cells. Lintuzumab also has the ability to induce apoptosis, or programmed cell death, in CD33-expressing leukemic cells. This dual mechanism of action makes Lintuzumab a potent therapeutic agent for the treatment of AML. Application of Lintuzumab ELISA Kit The Lintuzumab ELISA Kit is a valuable tool for researchers studying AML and the use of Lintuzumab as a therapeutic agent. It is a highly sensitive and specific assay that allows for the accurate quantification of Lintuzumab in various biological samples, such as serum, plasma, and cell culture supernatants. This is crucial in determining the pharmacokinetics and pharmacodynamics of Lintuzumab, as well as monitoring its levels during clinical trials. The Lintuzumab ELISA Kit can also be used to measure the levels of Lintuzumab in patient samples before and after treatment, providing valuable information on its efficacy and potential toxicity. This data can aid in the development of personalized treatment plans for AML patients. Furthermore, the Lintuzumab ELISA Kit can be used to screen potential Lintuzumab candidates in preclinical studies. This allows for the identification of the most effective Lintuzumab variants, which can then be further developed for clinical use. Future prospects The use of Lintuzumab as a therapeutic agent for AML is still in its early stages, with ongoing clinical trials evaluating its safety and efficacy. However, the promising results from preclinical studies and early clinical trials suggest that Lintuzumab has the potential to become a valuable addition to the current treatment options for AML. Conclusion In conclusion, the Lintuzumab ELISA Kit is a crucial tool for researchers studying Lintuzumab and its use as a therapeutic agent for AML. Its high sensitivity and specificity make it an ideal assay for the detection and quantification of Lintuzumab in various biological samples. With ongoing clinical trials and further research, Lintuzumab has the potential to improve the outcomes of AML patients and become a valuable addition to the current treatment options for this disease.

Lintuzumab ELISA Kit, Abbexa, abx395095

Lintuzumab ELISA Kit is a quantitative ELISA kit for detection of Lintuzumab.Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225Ac]Ac-lintuzumab clinical trials were discussed in detail in reference. An initial phase I dose-escalation trial demonstrated that for a single infusion of [225Ac]Ac-lintuzumab in patients with relapsed or refractory acute myeloid leukemia, the maximum tolerated dose (MTD) was determined to be 111 kBq/kg with antileukemic activity across all dose levels. No evidence of radiation-induced nephrotoxicity was seen. Peripheral blasts were eliminated in 63% of the patients at doses of >37 kBq/kg. Bone marrow blast reduction was observed in 67% of patients. Subsequently, a multicenter phase I dose-escalation trial was conducted to define MTD, toxicity, and response rate of fractionated-dose [225Ac]Ac-lintuzumab when combined with low-dose cytarabine (LDAC) in older patients with untreated AML who were not candidates for intensive chemotherapy.

Lintuzumab Biosimilar - Research Grade, ichor.bio, ICH5646

Research Grade Lintuzumab (HB185026), abinScience, HB185026